secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enliven Therapeutics, Inc. (ELVN)
CIK:        0001672619
Form:       8-K
Filed at:   2026-10-14T20:39:15+00:00
Accession:  0001193125-26-421761
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Enliven Therapeutics adds Kristine Ball to board; Phase 3 relcobatinib trial to start before year-end
--------------------------------------------------------------------------------

- Board expanded from seven to eight directors; Ball appointed Class II director effective Oct. 14, 2026, term expiring at the 2028 annual meeting, and joins the Audit Committee.
- Compensation: $45,000/year as outside director plus $10,000/year for Audit Committee service, and stock options with grant-date fair value of about $650,000.
- Options vest 1/36th monthly, with full acceleration on a Change in Control; Ball also signed the company's standard indemnification agreement.
- Ball was CEO of Antiva Biosciences and Soteria Biotherapeutics and CFO of Menlo Therapeutics and Relypsa; she chairs Oruka Therapeutics' audit committee.
- Company reaffirmed plans to initiate the pivotal Phase 3 trial of relcobatinib (ELVN-001) in previously treated CML before year-end 2026 after FDA alignment on ENABLE-2 design.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1672619/000119312526421761/0001193125-26-421761-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1672619/000119312526421761/d13112d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-421761

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer